GnRH agonist-associated pituitary apoplexy: a case series and review of the literature
- 9 April 2021
- journal article
- review article
- Published by Springer Nature in Pituitary
- Vol. 24 (5) , 681-689
Abstract
Purpose To examine the clinical presentation and longitudinal outcome of Pituitary Apoplexy (PA) after gonadotropin-releasing hormone agonist (GnRHa) in a series of patients and compare to prior reports. Methods A retrospective chart review was performed on seven patients receiving GnRHa who developed PA. Prior reported cases were analyzed. Results Six men (median age 72 years) with prostate cancer and one woman (aged 22 years) undergoing oocyte donation presented with PA between 1990 and 2020. Most presented with within 24 h of the first dose, but two developed PA 1 to 5 months after GnRHa initiation. The main clinical manifestations were headache (100%), nausea and vomiting (86%). While no patients had a previously known pituitary tumor, all had imaging demonstrating sellar mass and/or hemorrhage at presentation. Among those surgically treated (5/7), 80% (4/5) of patients had pathologic specimens that stained positive for gonadotropins; the remaining patient’s pathologic specimen was necrotic. At the time of PA, the most common pituitary dysfunction was hypocortisolism. Central adrenal insufficiency and central hypothyroidism were reversible in a subset. Pituitary imaging remained stable. Conclusions This is the first report of a case series with PA after GnRHa administration with longitudinal follow-up. Although infrequent, PA can be life-threatening and should be suspected among patients receiving GnRHa, with or without a known pituitary adenoma, who develop acute headache, nausea and/or vomiting. Since hypopituitarism was reversible in a subset, ongoing pituitary function testing may be indicated.Keywords
This publication has 40 references indexed in Scilit:
- Pituitary apoplexy induced by Gonadotropin-releasing hormone agonists for treating prostate cancer-report of first Asian caseWorld Journal of Surgical Oncology, 2013
- UK guidelines for the management of pituitary apoplexy a rare but potentially fatal medical emergencyEmergency Medicine Journal, 2010
- Unexpected enlargement of clinically silent pituitary gonadotroph adenoma induced by goserelin acetate given as treatment for prostate cancerInternational Journal of Urology, 2010
- Prevalence of pituitary adenomas: a community‐based, cross‐sectional study in Banbury (Oxfordshire, UK)Clinical Endocrinology, 2010
- Discovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancerInternational Journal of Urology, 2006
- Pituitary apoplexy after leuprolide injection for ovum donationJournal of Adolescent Health, 2003
- GonadotropinomasSeminars in Reproductive Medicine, 2002
- Precipitating factors in pituitary apoplexyJournal of Neurology, Neurosurgery & Psychiatry, 2001
- Pituitary apoplexy after leuprolide administration for carcinoma of the prostateClinical Endocrinology, 1996
- Pituitary apoplexy and sudden blindness following the administration of gonadotrophin releasing hormoneClinical Endocrinology, 1993